home / stock / lexx / lexx quote
Last: | $2.62 |
---|---|
Change Percent: | 0.72% |
Open: | $2.74 |
Close: | $2.62 |
High: | $2.74 |
Low: | $2.55 |
Volume: | 123,286 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.62 | $2.74 | $2.62 | $2.74 | $2.55 | 123,286 | 07-02-2024 |
$2.76 | $2.75 | $2.76 | $2.813 | $2.65 | 69,336 | 07-01-2024 |
$2.78 | $2.65 | $2.78 | $2.8297 | $2.5779 | 101,127 | 06-28-2024 |
$2.63 | $2.69 | $2.63 | $2.84 | $2.52 | 175,656 | 06-27-2024 |
$2.61 | $2.58 | $2.61 | $2.652 | $2.5 | 133,652 | 06-26-2024 |
$2.59 | $2.83 | $2.59 | $2.83 | $2.5 | 170,783 | 06-25-2024 |
$2.65 | $2.57 | $2.65 | $2.83 | $2.57 | 121,062 | 06-24-2024 |
$2.69 | $2.9 | $2.69 | $2.9 | $2.66 | 159,784 | 06-21-2024 |
$2.88 | $3 | $2.88 | $3.08 | $2.75 | 196,017 | 06-20-2024 |
$2.97 | $2.92 | $2.97 | $3.1 | $2.89 | 171,420 | 06-19-2024 |
$2.97 | $2.92 | $2.97 | $3.1 | $2.89 | 171,420 | 06-18-2024 |
$2.93 | $3.11 | $2.93 | $3.1724 | $2.76 | 255,030 | 06-17-2024 |
$3.09 | $3.31 | $3.09 | $3.35 | $2.99 | 97,177 | 06-14-2024 |
$3.29 | $3.28 | $3.29 | $3.63 | $3.26 | 151,635 | 06-13-2024 |
$3.24 | $3.24 | $3.24 | $3.27 | $3.1 | 75,164 | 06-12-2024 |
$3.07 | $3.27 | $3.07 | $3.29 | $3.05 | 82,905 | 06-11-2024 |
$3.27 | $3.3 | $3.27 | $3.35 | $3.1306 | 112,554 | 06-10-2024 |
$3.27 | $3.41 | $3.27 | $3.74 | $3.18 | 355,893 | 06-07-2024 |
$3.41 | $3.7 | $3.41 | $3.84 | $3.2701 | 296,580 | 06-06-2024 |
$3.81 | $3.96 | $3.81 | $4.11 | $3.74 | 171,010 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. Company Name:
LEXX Stock Symbol:
NASDAQ Market:
Lexaria Bioscience Corp. Website:
Lexaria Bioscience Corp. (NASDAQ: LEXX) , a global innovator in drug delivery platforms, is doubling down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. “The company is optimistic that the studies will yield positive results, not just in the potentia...
Lexaria, a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for its human pilot study #2 The final study arm is set for completion in early July, and if successful, it will help remedy the downsides of swallowed administration ...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to oversee execution of the company’s 12-week chronic study GLP-1-H24-4. The study will evaluate various DehydraTECH...